Harmony Biosciences (HRMY) Acquires Epygenix Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
April 30, 2024 7:00 AM EDTLead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024
Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy
PLYMOUTH MEETING, Pa., April 30, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of... More



